Get the Stockscreener App
4.585
1.82%
-0.085
Voyager Therapeutics Inc stock is traded at $4.585, with a volume of 382.80K.
It is down -1.82% in the last 24 hours and down -5.66% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$4.67
Open:
$4.67
24h Volume:
382.80K
Relative Volume:
0.51
Market Cap:
$254.20M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
7.0538
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-4.68%
1M Performance:
-5.66%
6M Performance:
+25.96%
1Y Performance:
-34.50%
1-Day Range:
$4.445
$4.68
1-Week Range:
$4.40
$4.84
52-Week Range:
$2.645
$7.4436
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.5827 | 259.04M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Sentiment analysis tools applied to Voyager Therapeutics Inc.Earnings Overview Report & Precise Buy Zone Tips - newser.com
Key resistance and support levels for Voyager Therapeutics Inc.2025 Historical Comparison & Stock Portfolio Risk Management - newser.com
Can Voyager Therapeutics Inc. stock hit record highs again2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Is Voyager Therapeutics Inc. stock a buy in volatile marketsWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
Using R and stats models for Voyager Therapeutics Inc. forecasting2025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Developing predictive dashboards with Voyager Therapeutics Inc. dataJuly 2025 Opening Moves & AI Based Buy/Sell Signal Reports - newser.com
Using portfolio simulators with Voyager Therapeutics Inc. included2025 Dividend Review & Weekly Market Pulse Updates - newser.com
Has Voyager Therapeutics Inc. formed a bullish divergenceMarket Risk Report & Short-Term High Return Ideas - newser.com
Is Voyager Therapeutics Inc. a candidate for recovery playJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Multi asset correlation models including Voyager Therapeutics Inc.Treasury Yields & Real-Time Stock Entry Alerts - newser.com
What drives Voyager Therapeutics Inc stock priceConsumer Goods Stocks & Free Daily Market Summary and Trend Reports - earlytimes.in
How institutional ownership impacts Voyager Therapeutics Inc. stock2025 Price Targets & Capital Protection Trade Alerts - newser.com
How high can Voyager Therapeutics Inc. stock go2025 Volatility Report & Stock Portfolio Risk Control - newser.com
Is Voyager Therapeutics Inc. stock attractive after correctionEarnings Growth Summary & Technical Pattern Based Buy Signals - newser.com
Voyager Therapeutics Advances Alzheimer’s Study with VY7523 - MSN
Voyager Therapeutics Stock Lost 5.1%, Buy Or Wait? - Trefis
Owning 44% shares,institutional owners seem interested in Voyager Therapeutics, Inc. (NASDAQ:VYGR), - Yahoo Finance
Can Voyager Therapeutics Inc. stock hit analyst price targetsProduct Launch & Safe Entry Momentum Tips - fcp.pa.gov.br
How Voyager Therapeutics Inc. stock compares to market leadersJuly 2025 Decliners & AI Driven Price Forecasts - fcp.pa.gov.br
How Voyager Therapeutics Inc. stock benefits from tech adoption2025 Price Targets & Free Community Supported Trade Ideas - Fundação Cultural do Pará
How to recover losses in Voyager Therapeutics Inc. stockJuly 2025 Levels & Real-Time Stock Movement Alerts - newser.com
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):